Sign in →

Test Code BRUTA Brucella Total Antibody Confirmation, Agglutination, Serum

Reporting Name

Brucella Ab, Agglutination, S

Useful For

Diagnosis of brucellosis

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Day(s) Performed

Wednesday, Friday

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86622

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BRUTA Brucella Ab, Agglutination, S 19053-8

 

Result ID Test Result Name Result LOINC Value
8112 Brucella Ab, Agglutination, S In Process

Clinical Information

Brucella species are facultative intracellular, gram-negative bacilli that cause brucellosis in humans. Human disease is likely acquired by contact with animals infected with the organism (Brucella abortus, Brucella suis, Brucella melitensis, and occasionally Brucella canis) either by direct contact or by ingestion of meat or milk. The signs and symptoms associated with brucellosis may include fever, night sweats, chills, weakness, malaise, headache, and anorexia. The physical examination may reveal lymphadenopathy and hepatosplenomegaly. A definitive diagnosis of brucellosis is made by recovering the organism from bone marrow, blood, fluid (including urine), or tissue specimens.

 

In cases of suspected brucellosis, serology may assist in the diagnosis and play a supplementary role in routine culture. Antibodies to Brucella species may not become detectable until 1 to 2 weeks following the onset of symptoms, so serum specimens collected during acute disease may be negative by serology in patients with brucellosis. If serology is performed, the Centers for Disease Control and Prevention currently recommends that specimens testing positive or equivocal for IgG or IgM by a screening enzyme immunoassay be confirmed by a Brucella-specific agglutination method.

Cautions

The tube agglutination assay was designed using antigen derived from Brucella abortus and may not be positive in patients infected with other Brucella species (eg, Brucella canis).

 

Positive results by Brucella serology are not diagnostic of acute infection, as antibodies may persist for months to years following exposure. To diagnose acute infection, detection of Brucella species in culture is the recommended approach (see BRUCB / Brucella Culture, Blood).

 

Brucella abortus strain RB51 is used for vaccination of animals in the United States. There are currently no serologic tests to detect an antibody response to strain RB51 in humans. Per Centers for Disease Control and Prevention guidelines, routine clinical serology tests for Brucella do not detect an antibody response to strain RB51. Note that other strains besides RB51 may be used for vaccinating animals outside of the United States.(2)

Report Available

2 to 7 days

Specimen Retention Time

14 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus OK

Method Name

Agglutination

Forms

If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.